Arca
Skip to content
Tools
Tools

Cough

Drug research and approvals for cough: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 18, 2026, 87 studies of cough are recruiting on ClinicalTrials.gov, Health Canada has authorized 19 drug trials for it since 2013, and the EU has 2 authorised medicines for it.

  • Recruiting worldwide: 87
  • Trials authorized in Canada: 19
  • FDA orphan approvals: 0
  • EU medicines: 2

Recruiting Now

Newest start dates first, of 87 recruiting on ClinicalTrials.gov ↗

Drug Pipeline

20 approved, 14 in phase 3, 32 in phase 2, 6 in phase 1 or earlier; from ChEMBL's drug indications, furthest stage reached for this condition

Approved: Gefapixant, Guaifenesin, Benzonatate, Codeine, Diphenhydramine, Dextromethorphan, Pseudoephedrine, Menthol, Camphor, Hydrocodone, Pholcodine, Zipeprol, Oxeladin, Clobutinol, Chlorpheniramine, Brompheniramine, Phenylephrine, Chlophedianol, Noscapine, Isoaminile

Lidocaine
Phase 3 Sodium channel alpha subunit blocker
Azithromycin
Phase 3 Bacterial 70S ribosome inhibitor
Syrup
Phase 3
Guaiacol
Phase 3
Bupivacaine
Phase 3 Sodium channel protein type IV alpha subunit blocker
Thalidomide
Phase 3 CRL4(CRBN) E3 ubiquitin ligase inhibitor
Ranitidine
Phase 3 Histamine H2 receptor antagonist
Triamcinolone acetonide
Phase 3 Glucocorticoid receptor agonist
Omeprazole
Phase 3 Potassium-transporting ATPase inhibitor
Eucalyptol
Phase 3
Oxolamine
Phase 3
Camlipixant
Phase 2 P2X purinoceptor 3 antagonist
SCH-486757
Phase 2 Nociceptin receptor agonist
Eliapixant
Phase 2
Albuterol
Phase 2 Beta-2 adrenergic receptor agonist
Montelukast
Phase 2 Cysteinyl leukotriene receptor 1 antagonist
Levocetirizine
Phase 2 Histamine H1 receptor antagonist
Orvepitant
Phase 2 Neurokinin 1 receptor antagonist
Bradanicline
Phase 2 Neuronal acetylcholine receptor protein alpha-7 subunit agonist
Indantadol
Phase 2 Glutamate [NMDA] receptor antagonist
XEN-D0501
Phase 2 Vanilloid receptor antagonist
Zinc acetate anhydrous
Phase 2 Skin protectant
Ambroxol
Phase 2
Carbetapentane
Phase 2 Sigma opioid receptor agonist

Showing the 30 furthest along of 52 in trials.

How Its Trials Ended

295 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 69 whose ending is known, 59% met their primary endpoint, 10% missed it and 30% stopped early.

  • Completed, result not reported12542%
  • Status unknown5519%
  • Ongoing4616%
  • Met its primary endpoint4114%
  • Stopped: other or unclear93%
  • Missed its primary endpoint72%
  • Stopped: lack of efficacy62%
  • Stopped: enrollment or feasibility62%

Trials Authorized in Canada

The 10 newest of 19; search them all in Canada trials
Sep 28, 2026A randomized, double-blind, placebo-controlled twelve-week fixed-dose study to evaluate the efficacy and safety of nalbuphine extended-release tablets for the…NalbuphineTrevi Therapeutics IncPending
May 22, 2026A randomized, double-blind, placebo-controlled dose-ranging study to evaluate the efficacy and safety of nalbuphine extended-release tablets for the treatment…NalbuphineTrevi Therapeutics IncOngoing
Nov 27, 2025A 2x2 factorial, randomized, open-label trial to evaluate neuromodulators and cough control therapy in patients with refractory or unexplained chronic cough:…Morphine / pregabalinMcmaster UniversityPending
Sep 3, 2025Understanding the role of airway mucus occlusions in canadians with asthma, copd and chronic cough (canmuc)Hyperpolarized XENON-129Mcmaster UniversityPending
Jun 30, 2025Assessing the efficacy of novel nasopharyngeal delivery system in alleviating post-nasal drip: a pilot studyCiclesonideResearch Institute Of The Mcgill University Health CentrePending
Feb 11, 2025A phase 3, 24-week, randomized, double-blind, placebo-controlled, parallelarm efficacy and safety study with open-label extension of blu-5937 in adult…Camlipixant (GSK5464714, BLU-5937)Bellus Health IncOngoing
Sep 26, 2024A phase 2b, randomized, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of taplucainium inhalation powder (noc-110) in…Taplucainium (NOC-110/NTX-1175)Nocion Therapeutics, IncOngoing
Aug 21, 2023A randomized, double-blind, placebo-controlled, parallel, 4-arm dose ranging study of the safety and efficacy of nal er tablets for the treatment of cough in…NalbuphineTrevi Therapeutics IncClosed
Aug 11, 2023A phase 2, double-blind, randomized, placebo-controlled, two-period crossover efficacy and safety study of nalbuphine er tablets for the treatment of…NalbuphineTrevi Therapeutics IncClosed
Nov 16, 2022A phase 3, 52-week, randomized, double-blind, placebo-controlled, parallel-arm efficacy and safety study with open-label extension of blu-5937 in adult…Camlipixant (BLU-5937)Bellus Health IncClosed

Medicines Authorised in the EU

Newest first
Jan 9, 2026VacPertagenPertussis vaccine (recombinant, acellular, component, adsorbed)BioNet EuropeEMA ↗
Sep 15, 2023LyfnuaGefapixantMerck Sharp & Dohme B.V.EMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.